chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Staphylococcus test positive, Tachypnoea, White blood cell count decreased
Clinical narrative: Patient is a 64 y.o. male patient of DO with history of stage IV Hodgkin lymphoma, HIV, bipolar depression, obstructive sleep apnea, GERD, chronic back pain, BPH, and hemorrhoids who presented to Hospital with weakness and diarrhea.  He was found to be covid positive on 3/17. Has been doing overall good and stable. Reached out to palliative for goals of care conversation. Patient notes he would like to be DNR CC and would like pain management with no medical management for his conditions. Hospice team has been following with patient, however, patient would like to go home for now. Discussed other options for hospice, as well as provided number for his oncology navigator who has been trying to get him established with hospice as well. At this time, stable for discharge and outpatient follow up.   Sepsis, resolved COVID 19 - 3/17 On presentation, hypertensive and tachypneic; leukopenic at 2.52; with lactic acidosis (2.4) COVID-positive Chest x-ray with possible bronchitis ED course - 30 cc/kg fluid bolus and IV Zosyn at this time Continue empiric IV Zosyn ID consulted. Appreciate input. Continue empiric antibiotics.   Palliative consulted for goals of care - Wants to focus on comfort care and is interested in utilizing support of hospice Referral to hospice placed.  Appreciate input from hospice as they formulate plan; patient requesting home hospice   Diarrhea, chronic, improved CT abdomen pelvis with mild central mesenteric edema and could indicate some form of mesenteric adenitis; as well as fluid in the proximal colon Blood cultures 1/2 with staph epi  Started on IV zosyn but discontinued after no bacterial etiology Continue IV fluids C. difficile negative Monitor   HIV infection DNR CC Last CD4 146 in December 2022 Patient was previously on Biktarvy, stopped treatment on his own Declines Biktarvy   Stage IV Hodgkin lymphoma DNR CC Diagnosed in June 2021 Underwent 5-6 cycles of chemotherapy, stopped treatment on his own WBC 2.52 CTPA with nonspecific mediastinal, right hilar, and periportal lymph nodes concerning for metastatic disease Pulmonary consulted during last admission 2 weeks ago as pt declined further therapy for his lymphoma and is not interested in further diagnostic evaluation.   Oncology consulted prior admission - Recommend PET CT scan outpatient if patient desires follow-up. Would need to follow-up back for surveillance and evaluate for recurrent disease. Palliative consulted as above.  CODE STATUS DNR CC
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthma, COVID-19, Chest X-ray abnormal, Condition aggravated
Clinical narrative: Patient is a 54 y.o. female patient of CNP with history of asthma and anxiety presented to a local Hospital with shortness of breath.   Acute hypoxemic respiratory failure Covid-19 Virus Infection Date of onset of symptoms: 3/20 Symptoms present on admission: soa Date of covid positive test: 3/27 Vaccination status: vaccinated Imaging: CXR no active disease, pulmonary hyperexpansion Oxygen requirements on admission: no oxygen at home  Current oxygen requirements: 2L upon DC on RA Medical therapy: remdesivir and steroids Consultants following: consulted ID  Anticipated special isolation end date: 4/6   Doing very well on room air  chest sounds clear Continuee above treatment and follow with ID  Discussed with ID , ok to discharge after 3rd dose of remdesivir    Asthma in acute exacerbation resolved  In the setting of COVID 19 infection Solumedol Albuterol QID Duo-nebs prn Muinex   Anxiety PRN hydroxyzine zoloft
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Lung hyperinflation, SARS-CoV-2 test positive
Clinical narrative: Patient is a 54 y.o. female patient of CNP with history of asthma and anxiety presented to a local Hospital with shortness of breath.   Acute hypoxemic respiratory failure Covid-19 Virus Infection Date of onset of symptoms: 3/20 Symptoms present on admission: soa Date of covid positive test: 3/27 Vaccination status: vaccinated Imaging: CXR no active disease, pulmonary hyperexpansion Oxygen requirements on admission: no oxygen at home  Current oxygen requirements: 2L upon DC on RA Medical therapy: remdesivir and steroids Consultants following: consulted ID  Anticipated special isolation end date: 4/6   Doing very well on room air  chest sounds clear Continuee above treatment and follow with ID  Discussed with ID , ok to discharge after 3rd dose of remdesivir    Asthma in acute exacerbation resolved  In the setting of COVID 19 infection Solumedol Albuterol QID Duo-nebs prn Muinex   Anxiety PRN hydroxyzine zoloft
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Inflammation, Pain in extremity, Peripheral swelling
Clinical narrative: patient called and said she started having sore and swollen arm after receiving shingirx on 04/14/23. Informed patient these are listed as side effects and suggested to the patient to take some antihistamine (benadryl, zyrtec, claritin) to help with the inflammation.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Disease complication, SARS-CoV-2 test positive
Clinical narrative: patient tested + for covid on 12-31-22  had a very complicated course.   admitted 12-31-22 to 3-1-23 at one facility and then transferred to another facility until 3-14-23.
Age: 26.0
Sex: M
Vaccine: COVID19-2
Symptoms: Unevaluable event
Clinical narrative: NONE
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: I don't have a lot of information other than tested positive for covid on         2-10-23                at      a local hospital lab                          and deceased 2-23-23
Age: 54.0
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: NONE
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: I don't have any info other than tested positive for covid on    9-12-22               at       Hospital                                         and deceased 10-29-22.
Age: 14.0
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: NONE
Age: 75.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Fear, Injection site haemorrhage, Muscle spasms, Wrong technique in product usage process
Clinical narrative: EXP date: 05/21/2024 2am started severe muscle, chest pain on the left side, and left leg muscle spasm, my left leg started twisting. Similar to my statin drug reactions.
Age: 75.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Blood test normal, Dyskinesia, Muscle spasms, Musculoskeletal chest pain
Clinical narrative: EXP date: 05/21/2024 2am started severe muscle, chest pain on the left side, and left leg muscle spasm, my left leg started twisting. Similar to my statin drug reactions.
Sex: M
Vaccine: HPV4
Symptoms: Product use issue
Clinical narrative: 8-years-old boyvaccinated for recurrent respiratory papillomatosis (RRP); 8-years-old boyvaccinated for recurrent respiratory papillomatosis (RRP);  Information has been received from the authors in a published literature article entitled as stated above concerning a 8-year-old male patient who was diagnosed with RRP (HPV serotype 6) at 22 months and required 26 surgeries by age six.   On an unspecified date, the patient failed adjuvant therapies, including quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection, , administered for respiratory papilloma (strength, dose description, lot #, expiry date, and route of administration were not provided), and nineteen intralesional bevacizumab injections. Systemic bevacizumab-awwb treatment was planned under pediatric oncology supervision (product used for unapproved indication) (Product use in unapproved population).   This is one of two reports received from the same source.  A copy of the published article is attached as further documentation of the patient's experience.; Sender's Comments:  US-009507513-2304USA005625:
Sex: F
Vaccine: HPV4
Symptoms: Condition aggravated, Respiratory papilloma, Surgery
Clinical narrative: 7-years-old girl vaccinated for recurrent respiratory papillomatosis (RRP); 7-years-old girl vaccinated for recurrent respiratory papillomatosis (RRP);   Information has been received from the authors in a published literature article entitled as stated above concerning a 7-year-old female patient who was diagnosed with RRP (HPV serotype 6) at 18 months and required 30 surgeries by age six.  On an unspecified date, the patient failed adjuvant therapies, including quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection, administered for respiratory papilloma (strength, dose description, lot #, expiry date, and route of administration were not provided), six intralesional modified vaccinia Ankara E2 virus vaccine injections, and four intralesional bevacizumab injections. Systemic bevacizumab-awwb treatment was planned under pediatric oncology supervision. (Product use in unapproved indication) (Product use in unapproved population).  This is one of two reports received from the same source.  A copy of the published article is attached as further documentation of the patient's experience.
Sex: M
Vaccine: COVID19
Symptoms: Off label use
Clinical narrative: RECEIVED 2ND BOOSTER DOSE WITH JANSSEN COVID-19 VACCINE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date in MAR-2021 for covid-19 prophylaxis. It was unknown whether the patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1).  The patient received first booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date for covid-19 prophylaxis. It was unknown whether the patient had any adverse events following vaccination with first booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2).  The patient received additionally second booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 3) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date for covid-19 prophylaxis which was associated with Off label dosing frequency (Off label use). The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patient received 2nd booster dose with JANSSEN COVID-19 VACCINE. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of received 2nd booster dose with JANSSEN COVID-19 VACCINE was not reported. This report was non-serious. This case, involving the same patient is linked to 20230433428.
Sex: M
Vaccine: COVID19
Symptoms: Adverse event
Clinical narrative: ADVERSE EVENT NOS; This spontaneous report received from a consumer concerned a 9 decade old male of unspecified race and ethnic origin. The patient's height, and weight were not reported. The patient's concurrent conditions included: immune issues, and other pre-existing medical conditions included: The patient had not gotten covid. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported) dose was not reported, 1 total administered on APR-2021 for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported) dose was not reported, 1 total administered on NOV-2021 for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient just got put into a nursing home (adverse event nos) (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of adverse event nos was not reported. This report was non-serious.
Sex: M
Vaccine: COVID19
Symptoms: Adverse event
Clinical narrative: GOT PUT INTO NURSING HOME; This spontaneous report received from a consumer concerned a 9 decade old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: immune issues, and other pre-existing medical conditions included: It was reported that patient did not get COVID so far. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date in APR-2021 for COVID-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1).  The patient additionally received second dose of covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date in NOV-2021 for COVID-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced got put into nursing home. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of got put into nursing home was not reported. This report was non-serious.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: RECEIVED HALF DOSE (0.25 ML); This spontaneous report received from a health care professional concerned a 64 year old male of unspecified race and ethnicity. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 207A21A expiry: 18-FEB-2023) 0.25 ml, 1 total, administered on 14-DEC-2021 for covid-19 prophylaxis. On 14-DEC-2021, the patient received half dose (0.25 ml) of vaccine (Dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin not reported, batch number: 207A21A expiry: 18-FEB-2023) 0.25 ml, 1 total, administered on 24-JUN-2022 for covid-19 prophylaxis. The drug was associated with Medication error. Age at time of vaccination 64 years old. No concomitant medications were reported.  On 24-JUN-2022, the patient received half dose (0.25 ml) of vaccine (Dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of received half dose (0.25 ml) was not reported. This report was non-serious. This case, involving the same patient is linked to 20230426062. This case, from the same reporter is linked to 20230426106.
Sex: M
Vaccine: COVID19
Symptoms: Off label use
Clinical narrative: RECEIVED 3RD BOOSTER DOSE OF JANSSEN COVID-19 VACCINE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date in MAR-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1).  The patient previously received first booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2). The patient previously received second booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 3) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on unspecified date for covid-19 prophylaxis. The drug was associated with Off label dosing frequency (Off label use) (dose number in series 3). The patient received additionally third booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 4) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 total, administered on 20-SEP-2022 for covid-19 prophylaxis which was associated with Off label dosing frequency (Off label use). The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On 20-SEP-2022, the patient received 3rd booster dose (Off label use) of JANSSEN COVID-19 VACCINE (dose number in series 4). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of received 3rd booster of JANSSEN COVID-19 VACCINE was not reported. This report was non-serious. This case, involving the same patient is linked.
Age: 0.17
Sex: F
Vaccine: DTAPIPV
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: two-month-old patient was mistakenly administered a quadracel vaccine with no reported adverse event; Initial information received on 10-Apr-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 2 months old female patient and it was reported that mistakenly administered a diphtheria-15/tetanus/5 hybrid AC pertussis/IPV (MRC5) vaccine [Quadracel] with no reported adverse event.   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included pneumococcal vaccine CONJ 7V (CRM197) (Prevnar); rotavirus vaccine; and hepatitis B vaccine all for Prophylactic vaccination.  On 23-Jan-2023, two-month-old patient was mistakenly administered 0.5 mL of diphtheria-15/tetanus/5 hybrid AC pertussis/IPV (MRC5) vaccine [Quadracel] suspension for injection (batch/lot number: UJ737AA, expiry date: 18-Sep-2023, strength: standard; 1X) via intramuscular route in the left thigh for immunization with no reported adverse event (product administered to patient of inappropriate age) (latency: same day)  Action taken: Not applicable.  At time of reporting, the outcome was Unknown for the event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 6.0
Sex: M
Vaccine: DTAP
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Pentacel components were all given separately and an extra dose was given by accident with no reported adverse event; Initial information received on 11-Apr-2023 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 6 years old male patient and reporter reported that pentacel components were all given separately and an extra dose of diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] was given by accident with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included hepatitis B vaccine for Prophylactic vaccination; and measles vaccine, mumps vaccine, rubella vaccine (MMR) for Prophylactic vaccination.  On 12-Jan-2022, the patient received 0.5 ml (milliliter) of suspect diphtheria-15/tetanus/5 AC pertussis vaccine, suspension for injection (lot C5765BA, expiry date: 28-Aug-2022) via intramuscular route (With unknown strength and at unknown administration site) for immunization.  On 12-Jan-2022, reporter reported that pentacel components were all given separately and an extra dose was given by accident with no reported adverse event (extra dose administered) (latency: same day).  No lab data were reported.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: VARZOS
Symptoms: Erythema, Injection site pain
Clinical narrative: A big red spot on my arm; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of erythema of extremities in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine with an associated reaction of injection site pain (on an unknown date the patient received the 1st dose and felt pain of the needle, refer case US2023AMR052227).   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced erythema of extremities (Verbatim: A big red spot on my arm). The outcome of the erythema of extremities was resolved.   It was unknown if the reporter considered the erythema of extremities to be related to Shingles vaccine.     It was unknown if the company considered the erythema of extremities to be related to Shingles vaccine.   Linked case(s) involving the same patient:  US2023AMR052227   Additional Information: GSK Receipt Date: 07-APR-2023 This case was reported the patient via interactive digital media. The patient got a big red spot on his/her arm. But it was only for a couple days. Way better than getting shingles. This case is linked with US2023AMR052243 and US2023AMR052242, reported by the same reporter. The follow-up could not be possible as no contact details were available.; Sender's Comments:  US-GSK-US2023AMR052227:same reporter - 1st dose US-GSK-US2023AMR052242:same reporter US-GSK-US2023AMR052243:same reporter
Age: 2.0
Sex: M
Vaccine: COVID19-2
Symptoms: Product formulation issue
Clinical narrative: Error: Wrong Vaccine Formulation (ex. Prevnar 13 v. Prevnar 23)-
Age: 29.0
Sex: F
Vaccine: HEP
Symptoms: Dizziness, Hypotension, Malaise, Nausea, Syncope
Clinical narrative: Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Medium, Systemic: Hypotension-Medium, Systemic: Nausea-Medium, Systemic: Visual Changes/Disturbances-Medium, Additional Details: She reported to me that after the engerix-b she did not feel well. She expressed she felt a little dizzy/nauseaous, as well as some visual disturbances. She was exhibiting symptoms of syncope. I followed up with checking her blood pressure, it was a little low, but not concerning. She nodded off a few times, but she was awake and responsive when speaking to her. EMTs came to be sure she was okay, and she was evaluated and okay. She left feeling okay, and she denied hospital visit.
Age: 29.0
Sex: F
Vaccine: HEP
Symptoms: Unresponsive to stimuli, Visual impairment
Clinical narrative: Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Medium, Systemic: Hypotension-Medium, Systemic: Nausea-Medium, Systemic: Visual Changes/Disturbances-Medium, Additional Details: She reported to me that after the engerix-b she did not feel well. She expressed she felt a little dizzy/nauseaous, as well as some visual disturbances. She was exhibiting symptoms of syncope. I followed up with checking her blood pressure, it was a little low, but not concerning. She nodded off a few times, but she was awake and responsive when speaking to her. EMTs came to be sure she was okay, and she was evaluated and okay. She left feeling okay, and she denied hospital visit.
Age: 15.0
Sex: F
Vaccine: TDAP
Symptoms: Asthenia
Clinical narrative: Systemic: Weakness-Medium
Age: 47.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  All Pfizer dose 1  3/26/21  ER8730 dose 2  4/16/21  EW0164 dose 3  10/1/21  FF2588
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Condition aggravated, Epilepsy, Immediate post-injection reaction, Loss of consciousness
Clinical narrative: Immediately became weak, passed out when released to walk to car, vomited. Had an epileptic episode. Pharmacy staff asked me to stay or go by ambulance to hospital.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Immediately became weak, passed out when released to walk to car, vomited. Had an epileptic episode. Pharmacy staff asked me to stay or go by ambulance to hospital.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, Blood test, Chest pain, Fatigue, Gait disturbance
Clinical narrative: I experienced chest pains and started to feel really tired, I got to the point to where I could barely walk small distances without getting very tired and fatigued. I went to the emergency room and they discovered blood clots and I was in the hospital for 9 days, they gave me a specific medication that I don't know the name of, but they was trying to get my IMT within a certain level before they could release me so every 4 hours they would take blood work to see where my IMT level was before they release me from the hospital  to start taking blood thinners and I am taking blood thinners for the rest of my life.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Immune thrombocytopenia, Thrombosis
Clinical narrative: I experienced chest pains and started to feel really tired, I got to the point to where I could barely walk small distances without getting very tired and fatigued. I went to the emergency room and they discovered blood clots and I was in the hospital for 9 days, they gave me a specific medication that I don't know the name of, but they was trying to get my IMT within a certain level before they could release me so every 4 hours they would take blood work to see where my IMT level was before they release me from the hospital  to start taking blood thinners and I am taking blood thinners for the rest of my life.
Age: 58.0
Sex: M
Vaccine: VARZOS
Symptoms: Headache, Injection site inflammation, Myalgia, Nausea, Pain in extremity
Clinical narrative: severe headache and nausea - lasted approximately 40 hours.  inflammation at injection site - 4" circle - lasted 30 hours. Very sore arm (right arm) muscle aches.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Arthritis, Arthropathy, Autoimmune disorder, Blood test normal, Humerus fracture
Clinical narrative: As already noted, my body has reacted with an autoimmune attack on my joints.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Laboratory test normal, Magnetic resonance imaging joint, Rotator cuff repair, Rotator cuff syndrome, X-ray
Clinical narrative: As already noted, my body has reacted with an autoimmune attack on my joints.
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test normal, COVID-19, Endotracheal intubation, Hyporesponsive to stimuli, Hypoxia
Clinical narrative: Hospital Course: Patient is an 86 year old female with a history of advance dementia, CAD, hyperlipidemia, and CKD who presented to hospital on 4/7/23 with decreased responsiveness. On arrival she was noted to be febrile and hypoxic with a GCS 6 requiring intubation and admission to the ICU. Infectious workup grossly negative with the exception of being COVID +. She was successfully extubated and stable for transfer to the general medical floors. She was provided supportive care as remaining infectious work up was largely negative. Patient continued to improve each day. She was discharged in stable condition to her home. Her sister will be taking care of her. Home care will be provided. Hospital bed also provided.
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Intensive care, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Hospital Course: Patient is an 86 year old female with a history of advance dementia, CAD, hyperlipidemia, and CKD who presented to hospital on 4/7/23 with decreased responsiveness. On arrival she was noted to be febrile and hypoxic with a GCS 6 requiring intubation and admission to the ICU. Infectious workup grossly negative with the exception of being COVID +. She was successfully extubated and stable for transfer to the general medical floors. She was provided supportive care as remaining infectious work up was largely negative. Patient continued to improve each day. She was discharged in stable condition to her home. Her sister will be taking care of her. Home care will be provided. Hospital bed also provided.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Aspiration, COVID-19, Enteral nutrition, Epistaxis, Hypoxia
Clinical narrative: Brief Summary of Hospital Stay: Patient is a 56 year old female with a history of cerebral palsy, asthma, hypertension, scoliosis, and seizures and is a resident of local AFC who presents to the ED with cough as well as an episode of vomiting (witnessed aspiration) associated with hypoxia.  Hypoxia quickly resolved.  Patient during hospitalization treated with a full 5 day course of doxycycline and ceftriaxone for aspiration event pneumonia.  Patient also testing positive for COVID and initially treated 3 day course of remdesivir although with development of hypoxia changed over to dexamethasone although hypoxia resolved by 4/11.  Patient to continue dexamethasone however to complete 10 day course with 7 more doses.  Of note patient had transient epistaxis episode which did not recur during hospitalization.  Patient discharged back to AFC on 04/12 and was stable at time of discharge although continued to have upper respiratory breath sounds but maintain saturations and did not appear to be in respiratory distress.  Dietitian manage tube feeds during hospitalization and change tube feeds to Jevity 1.5 on carton 3 times a day with 30 mL flush of water before and after each feeding as well as 250 mL of fluid 2 hours after each feeding (spaced out to diminish residuals and decrease chance of vomiting).   Wound care nurse evaluated right antecubital wound and give the following recommendations:  Right AC: Cleanse with normal saline. Pat dry. Cover with optifoam gentle. Change 3 times weekly and PRN loose or soiled.  Place interdry in Right elbow fold.    Skin care to Left AC: Cleanse with warm wet wash cloth and Remedy cleanser and moisturizer. Pat dry. Apply caldesene powder and dust off excess. Place interdry in left elbow fold. Perform every shift and PRN incontinence or excessive moisture.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pneumonia aspiration, SARS-CoV-2 test positive, Vomiting, Wound
Clinical narrative: Brief Summary of Hospital Stay: Patient is a 56 year old female with a history of cerebral palsy, asthma, hypertension, scoliosis, and seizures and is a resident of local AFC who presents to the ED with cough as well as an episode of vomiting (witnessed aspiration) associated with hypoxia.  Hypoxia quickly resolved.  Patient during hospitalization treated with a full 5 day course of doxycycline and ceftriaxone for aspiration event pneumonia.  Patient also testing positive for COVID and initially treated 3 day course of remdesivir although with development of hypoxia changed over to dexamethasone although hypoxia resolved by 4/11.  Patient to continue dexamethasone however to complete 10 day course with 7 more doses.  Of note patient had transient epistaxis episode which did not recur during hospitalization.  Patient discharged back to AFC on 04/12 and was stable at time of discharge although continued to have upper respiratory breath sounds but maintain saturations and did not appear to be in respiratory distress.  Dietitian manage tube feeds during hospitalization and change tube feeds to Jevity 1.5 on carton 3 times a day with 30 mL flush of water before and after each feeding as well as 250 mL of fluid 2 hours after each feeding (spaced out to diminish residuals and decrease chance of vomiting).   Wound care nurse evaluated right antecubital wound and give the following recommendations:  Right AC: Cleanse with normal saline. Pat dry. Cover with optifoam gentle. Change 3 times weekly and PRN loose or soiled.  Place interdry in Right elbow fold.    Skin care to Left AC: Cleanse with warm wet wash cloth and Remedy cleanser and moisturizer. Pat dry. Apply caldesene powder and dust off excess. Place interdry in left elbow fold. Perform every shift and PRN incontinence or excessive moisture.
Age: 79.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Appendicectomy, Appendicitis, Bacteroides bacteraemia, Laparoscopic surgery, SARS-CoV-2 test positive
Clinical narrative: Hospital Course:  80 yo M with h/o CAD, HTN, Hypothryoidism, BPH with mild COVID-19 x 4 days pta who was admitted with acute appendicitis, complicated by Bacteroides bacteremia. Patient underwent a laparoscopic appendectomy for acute appendicitis. He tolerated his procedure well. He was treated initially with zosyn. On POD2 he was transitioned from zosyn to metronidazole and is to complete a total 14 day course of antibiotics. He should follow up with his surgeon on 4/20 and his primary care physician.    Issues Requiring Follow Up:  - Completion of antibiotics; Flagyl for a total of 14 days - Follow up with primary care physician - Follow up with surgeon 4/20  - Hydronephrosis incidentally seen on imagining, follow up outpt
Age: 41.0
Sex: F
Vaccine: PNC20
Symptoms: Abdominal pain, Chills, Diarrhoea, Erythema, Nausea
Clinical narrative: Pnucn20  gave me swelling, pain, and redness to left are to the area of sight within a short time. Several hours later I began having abdominal cramping with nausea, vomiting, diarrhea, chills, and fever that lasted several hours.
Age: 41.0
Sex: F
Vaccine: PNC20
Symptoms: Pain, Pyrexia, Swelling, Vomiting
Clinical narrative: Pnucn20  gave me swelling, pain, and redness to left are to the area of sight within a short time. Several hours later I began having abdominal cramping with nausea, vomiting, diarrhea, chills, and fever that lasted several hours.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Acute myocardial infarction, Brain natriuretic peptide increased, COVID-19, Catheterisation cardiac abnormal, Chest pain
Clinical narrative: Heart Cath 4/11/2023, Dr   1. Coronary artery disease as follows: 100% distal right coronary artery culprit lesion, 70% mid LAD, 70-80% distal LAD, 50% mid circumflex artery, 50-60% mid 1st obtuse marginal branch. 2. Successful PTCA stent mid right coronary artery with a 3.55 x 18 mm drug-eluting stent, successful PTCA stent distal right coronary artery/PDA with a 3 mm x 38 mm drug-eluting stent. 3. Mild LV dysfunction with ejection fraction of 45-50% with severe inferior apical hypokinesis. 4. No significant mitral regurgitation. 5. No aortic stenosis. 6. Mildly elevated left ventricular end-diastolic pressure of 20 mmHg.   Echo 4/11/2023 1. Left Ventricle: Left ventricle cavity appears normal. Wall thickness is normal. Systolic function is mildly decreased with an ejection fraction of 50 - 55%. Regional wall motion abnormalities present.  Inferior wall hypokinesia There is no diastolic dysfunction.   Hospital Course: Patient is a 71 year-old Male who presented via EMS due to complaints of crushing chest pain, Left arm pain, and diaphoresis  that started at 4/11 at 800 when he was raking the leaves. EKG in field significant for STEMI in inferior posterior aspect. In the ED, Vitals : 97.2F, 56 HR, 18 RR, 121/76, 97% RA, Labs significant for Trope 2120-- >2823, BNP 389 and positive Covid-19 test.  Patient admitted to cardiology team with emergent heart-cath. Heart cath performed by Dr showed complete RCA occlusion requiring 2x DES, notable 70% occlusion of mid LAD and 70-80% distal LAD, 50% mid circumflex and 0-60% obtuse marginal artery.  Echocardiogram obtained  showed EF of 50-55% with regional wall motion abnormalities, inferior wall hypokinesis with history of diastolic dysfunction.  Patient was initiated on DAPT: ASA and  Prasugrel, Lisinopril, and Metoprolol. Patients COVID symptoms remained stable with no significant symptomatology besides occasional cough. Pts hospital course not complicated and patient was discharged with instructions to follow-up with pcp, Cardiology while obtaining stress test and referral for cardiac rehab.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Coronary angioplasty, Coronary arterial stent insertion, Coronary artery disease, Coronary artery occlusion, Cough
Clinical narrative: Heart Cath 4/11/2023, Dr   1. Coronary artery disease as follows: 100% distal right coronary artery culprit lesion, 70% mid LAD, 70-80% distal LAD, 50% mid circumflex artery, 50-60% mid 1st obtuse marginal branch. 2. Successful PTCA stent mid right coronary artery with a 3.55 x 18 mm drug-eluting stent, successful PTCA stent distal right coronary artery/PDA with a 3 mm x 38 mm drug-eluting stent. 3. Mild LV dysfunction with ejection fraction of 45-50% with severe inferior apical hypokinesis. 4. No significant mitral regurgitation. 5. No aortic stenosis. 6. Mildly elevated left ventricular end-diastolic pressure of 20 mmHg.   Echo 4/11/2023 1. Left Ventricle: Left ventricle cavity appears normal. Wall thickness is normal. Systolic function is mildly decreased with an ejection fraction of 50 - 55%. Regional wall motion abnormalities present.  Inferior wall hypokinesia There is no diastolic dysfunction.   Hospital Course: Patient is a 71 year-old Male who presented via EMS due to complaints of crushing chest pain, Left arm pain, and diaphoresis  that started at 4/11 at 800 when he was raking the leaves. EKG in field significant for STEMI in inferior posterior aspect. In the ED, Vitals : 97.2F, 56 HR, 18 RR, 121/76, 97% RA, Labs significant for Trope 2120-- >2823, BNP 389 and positive Covid-19 test.  Patient admitted to cardiology team with emergent heart-cath. Heart cath performed by Dr showed complete RCA occlusion requiring 2x DES, notable 70% occlusion of mid LAD and 70-80% distal LAD, 50% mid circumflex and 0-60% obtuse marginal artery.  Echocardiogram obtained  showed EF of 50-55% with regional wall motion abnormalities, inferior wall hypokinesis with history of diastolic dysfunction.  Patient was initiated on DAPT: ASA and  Prasugrel, Lisinopril, and Metoprolol. Patients COVID symptoms remained stable with no significant symptomatology besides occasional cough. Pts hospital course not complicated and patient was discharged with instructions to follow-up with pcp, Cardiology while obtaining stress test and referral for cardiac rehab.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Echocardiogram abnormal, Ejection fraction decreased, Electrocardiogram abnormal, Hyperhidrosis, Left ventricular dysfunction
Clinical narrative: Heart Cath 4/11/2023, Dr   1. Coronary artery disease as follows: 100% distal right coronary artery culprit lesion, 70% mid LAD, 70-80% distal LAD, 50% mid circumflex artery, 50-60% mid 1st obtuse marginal branch. 2. Successful PTCA stent mid right coronary artery with a 3.55 x 18 mm drug-eluting stent, successful PTCA stent distal right coronary artery/PDA with a 3 mm x 38 mm drug-eluting stent. 3. Mild LV dysfunction with ejection fraction of 45-50% with severe inferior apical hypokinesis. 4. No significant mitral regurgitation. 5. No aortic stenosis. 6. Mildly elevated left ventricular end-diastolic pressure of 20 mmHg.   Echo 4/11/2023 1. Left Ventricle: Left ventricle cavity appears normal. Wall thickness is normal. Systolic function is mildly decreased with an ejection fraction of 50 - 55%. Regional wall motion abnormalities present.  Inferior wall hypokinesia There is no diastolic dysfunction.   Hospital Course: Patient is a 71 year-old Male who presented via EMS due to complaints of crushing chest pain, Left arm pain, and diaphoresis  that started at 4/11 at 800 when he was raking the leaves. EKG in field significant for STEMI in inferior posterior aspect. In the ED, Vitals : 97.2F, 56 HR, 18 RR, 121/76, 97% RA, Labs significant for Trope 2120-- >2823, BNP 389 and positive Covid-19 test.  Patient admitted to cardiology team with emergent heart-cath. Heart cath performed by Dr showed complete RCA occlusion requiring 2x DES, notable 70% occlusion of mid LAD and 70-80% distal LAD, 50% mid circumflex and 0-60% obtuse marginal artery.  Echocardiogram obtained  showed EF of 50-55% with regional wall motion abnormalities, inferior wall hypokinesis with history of diastolic dysfunction.  Patient was initiated on DAPT: ASA and  Prasugrel, Lisinopril, and Metoprolol. Patients COVID symptoms remained stable with no significant symptomatology besides occasional cough. Pts hospital course not complicated and patient was discharged with instructions to follow-up with pcp, Cardiology while obtaining stress test and referral for cardiac rehab.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Left ventricular end-diastolic pressure increased, Malaise, Pain in extremity, Patent ductus arteriosus, SARS-CoV-2 test positive
Clinical narrative: Heart Cath 4/11/2023, Dr   1. Coronary artery disease as follows: 100% distal right coronary artery culprit lesion, 70% mid LAD, 70-80% distal LAD, 50% mid circumflex artery, 50-60% mid 1st obtuse marginal branch. 2. Successful PTCA stent mid right coronary artery with a 3.55 x 18 mm drug-eluting stent, successful PTCA stent distal right coronary artery/PDA with a 3 mm x 38 mm drug-eluting stent. 3. Mild LV dysfunction with ejection fraction of 45-50% with severe inferior apical hypokinesis. 4. No significant mitral regurgitation. 5. No aortic stenosis. 6. Mildly elevated left ventricular end-diastolic pressure of 20 mmHg.   Echo 4/11/2023 1. Left Ventricle: Left ventricle cavity appears normal. Wall thickness is normal. Systolic function is mildly decreased with an ejection fraction of 50 - 55%. Regional wall motion abnormalities present.  Inferior wall hypokinesia There is no diastolic dysfunction.   Hospital Course: Patient is a 71 year-old Male who presented via EMS due to complaints of crushing chest pain, Left arm pain, and diaphoresis  that started at 4/11 at 800 when he was raking the leaves. EKG in field significant for STEMI in inferior posterior aspect. In the ED, Vitals : 97.2F, 56 HR, 18 RR, 121/76, 97% RA, Labs significant for Trope 2120-- >2823, BNP 389 and positive Covid-19 test.  Patient admitted to cardiology team with emergent heart-cath. Heart cath performed by Dr showed complete RCA occlusion requiring 2x DES, notable 70% occlusion of mid LAD and 70-80% distal LAD, 50% mid circumflex and 0-60% obtuse marginal artery.  Echocardiogram obtained  showed EF of 50-55% with regional wall motion abnormalities, inferior wall hypokinesis with history of diastolic dysfunction.  Patient was initiated on DAPT: ASA and  Prasugrel, Lisinopril, and Metoprolol. Patients COVID symptoms remained stable with no significant symptomatology besides occasional cough. Pts hospital course not complicated and patient was discharged with instructions to follow-up with pcp, Cardiology while obtaining stress test and referral for cardiac rehab.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Troponin increased, Ventricular hypokinesia
Clinical narrative: Heart Cath 4/11/2023, Dr   1. Coronary artery disease as follows: 100% distal right coronary artery culprit lesion, 70% mid LAD, 70-80% distal LAD, 50% mid circumflex artery, 50-60% mid 1st obtuse marginal branch. 2. Successful PTCA stent mid right coronary artery with a 3.55 x 18 mm drug-eluting stent, successful PTCA stent distal right coronary artery/PDA with a 3 mm x 38 mm drug-eluting stent. 3. Mild LV dysfunction with ejection fraction of 45-50% with severe inferior apical hypokinesis. 4. No significant mitral regurgitation. 5. No aortic stenosis. 6. Mildly elevated left ventricular end-diastolic pressure of 20 mmHg.   Echo 4/11/2023 1. Left Ventricle: Left ventricle cavity appears normal. Wall thickness is normal. Systolic function is mildly decreased with an ejection fraction of 50 - 55%. Regional wall motion abnormalities present.  Inferior wall hypokinesia There is no diastolic dysfunction.   Hospital Course: Patient is a 71 year-old Male who presented via EMS due to complaints of crushing chest pain, Left arm pain, and diaphoresis  that started at 4/11 at 800 when he was raking the leaves. EKG in field significant for STEMI in inferior posterior aspect. In the ED, Vitals : 97.2F, 56 HR, 18 RR, 121/76, 97% RA, Labs significant for Trope 2120-- >2823, BNP 389 and positive Covid-19 test.  Patient admitted to cardiology team with emergent heart-cath. Heart cath performed by Dr showed complete RCA occlusion requiring 2x DES, notable 70% occlusion of mid LAD and 70-80% distal LAD, 50% mid circumflex and 0-60% obtuse marginal artery.  Echocardiogram obtained  showed EF of 50-55% with regional wall motion abnormalities, inferior wall hypokinesis with history of diastolic dysfunction.  Patient was initiated on DAPT: ASA and  Prasugrel, Lisinopril, and Metoprolol. Patients COVID symptoms remained stable with no significant symptomatology besides occasional cough. Pts hospital course not complicated and patient was discharged with instructions to follow-up with pcp, Cardiology while obtaining stress test and referral for cardiac rehab.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Fatigue, Nasal congestion, Pyrexia
Clinical narrative: I experienced a breakthrough case of COVID-19 with sneezing, nasal congestion, fatigue, fever and chills.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Sneezing, Vaccine breakthrough infection
Clinical narrative: I experienced a breakthrough case of COVID-19 with sneezing, nasal congestion, fatigue, fever and chills.
Age: 36.0
Sex: F
Vaccine: HEP
Symptoms: Underdose
Clinical narrative: Patient was incorrectly given pediatric dose instead of adult dose.